Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216739 | 0.90 | DHODH (0.72) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL3920472 | 0.86 | CETP (0.55) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL16383807 | 0.84 | DHODH (0.76) | DHODHHTR3AMTNR1AMTNR1BESR2 | |
| SCHEMBL16383806 | 0.83 | DHODH (0.62) | DHODHIKBKBHTR3AMTNR1AMTNR1B | |
| SCHEMBL19664247 | 0.81 | RAB9A (0.48) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL18951247 | 0.78 | PTPN2 (0.45) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL3919291 | 0.78 | CEPT1 (0.50) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL3920913 | 0.77 | ESR2 (0.50) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL3920310 | 0.77 | ESR1 (0.43) | DHODHIKBKBHDAC3HDAC1HDAC2 | |
| SCHEMBL441953 | 0.77 | DHODH (0.65) | DHODHPARP1PTPN1PTPN2PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | DHODH 3744/4885IKBKB 1113/4885HDAC3 52/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | DHODH 3746/4885IKBKB 1507/4885HDAC3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.